Biohaven Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Biohaven Pharmaceuticals's estimated annual revenue is currently $26M per year.
- Biohaven Pharmaceuticals received $143.7M in venture funding in December 2018.
- Biohaven Pharmaceuticals's estimated revenue per employee is $144,667
- Biohaven Pharmaceuticals's total funding is $248.3M.
- Biohaven Pharmaceuticals has 180 Employees.
- Biohaven Pharmaceuticals grew their employee count by 195% last year.
- Biohaven Pharmaceuticals currently has 34 job openings.
|Gene Dubowchik||VP Chemistry, Research and Development|
|Mark Glackin||Vice President, Migraine Sales & Marketing|
|Robert Croop||Chief Development Officer - Neurology|
|Francine Healy||Executive Director|
|Ashwini Ghatpande||Vice President, Scientific Writing and Regulatory Submissions|
|Marianne Frost||Executive Director|
|Andrea Ivans||Director, Clinical Operations|
|Victoria Wirtz||Sr Director, Biostatistics|
|Clifford Bechtold||Chief Operating Officer|
|David Loomis||VP & Corporate Controller|
What Is Biohaven Pharmaceuticals?
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company's first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Biohaven Pharmaceuticals News
Submitted Two New Drug Applications (NDAs) to FDA for Zydis® Orally Dissolving Tablet (ODT) and tablet formulations of rimegepant in the ...
The recent performance of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock in the market spoke loud and clear to ...
Biohaven Pharmaceutical Holding Company (BHVN +7.3%) is up, albeit on light volume, in reaction its corporate update that includes an ...
Biohaven Pharmaceuticals Funding
|2018-12-13||$143.7M||Undisclosed||Goldman Sachs & Co. LLC||Article|
Biohaven Pharmaceuticals Executive Hires
|2017-06-23||Elyse Stock||Chief of Portfolio Strategy and Development||Article|
|2017-10-26||Clifford Bechtold||Chief Operating Officer||Article|
|2017-11-13||Scott Phillips||SVP Finance||Article|